APR September/October 2020 - 34

Thermo Fisher Scientific
168 Third Avenue
Waltham, MA USA 02451
Tel: 800-678-5599

www.thermofisher.com/patheon
COMPANY DESCRIPTION

recent additions like Patheon Viral Vector Services (formerly

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in
serving science, with annual revenue exceeding $25 billion. Our
Mission is to enable our customers to make the world healthier,
cleaner and safer. Whether our customers are accelerating
life sciences research, solving complex analytical challenges,
improving patient diagnostics and therapies or increasing
productivity in their laboratories, we are here to support them. Our
global team of more than 75,000 colleagues delivers an unrivaled
combination of innovative technologies, purchasing convenience
and pharmaceutical services through our industry-leading brands,
including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher
Scientific, Unity Lab Services and Patheon.

Brammer Bio), we have simplified our branding by aligning all
CDMO and Clinical Service offerings under the Patheon brand. We
are an integrated force and stronger than ever. Built on a proven
foundation of quality systems and commitment to continuous
improvement, we have the capabilities and expertise to help you
achieve success in drug development.

MARKETS SERVED/FACILITIES
With more than 55 locations across North America, Europe,
Asia and Australia, Thermo Fisher's Pharma Services business
can provide integrated, end-to-end capabilities across all
phases of development, including API, biologics, viral vectors,
formulation, clinical trials solutions, logistics services and commercial manufacturing.

PRODUCTS/SERVICES/CAPABILITIES
Thermo Fisher Scientific's Pharma Services provide industryleading pharma services solutions for drug development, clinical
trial logistics and commercial manufacturing to customers of all
sizes. Our global leadership is built on a reputation for scientific
and technical excellence. This includes specialized capabilities for
highly potent and controlled substances, viral vector expertise,
aseptic filling and lyophilization, complex formulations, solubility
enhancement and difficult-to-manufacture APIs. We also offer

COMPANY BACKGROUND

integrated services for drug development that aligns development

Our Thermo Fisher Scientific Pharma Services business was

toward proof of concept that can reduce development timelines.

created by combining the CDMO capabilities of Patheon and the

As a leading global CDMO, we deliver unrivaled quality, reliability

clinical trial capabilities of Fisher Clinical Services . With other

and compliance.

of drug substance and drug product in a coordinated drive

SM

34 |

Thermo_2020Profile.indd 34
APR_SeptOct2020.indd
1

| September/October 2020

10/2/20
9/29/20 11:45
8:04 PM
AM



http://www.thermofisher.com/patheon

APR September/October 2020

Table of Contents for the Digital Edition of APR September/October 2020

Table of Contents
APR September/October 2020 - Cover1
APR September/October 2020 - Cover2
APR September/October 2020 - 1
APR September/October 2020 - 2
APR September/October 2020 - Table of Contents
APR September/October 2020 - 4
APR September/October 2020 - 5
APR September/October 2020 - 6
APR September/October 2020 - 7
APR September/October 2020 - 8
APR September/October 2020 - 9
APR September/October 2020 - 10
APR September/October 2020 - 11
APR September/October 2020 - 12
APR September/October 2020 - 13
APR September/October 2020 - 14
APR September/October 2020 - 15
APR September/October 2020 - 16
APR September/October 2020 - 17
APR September/October 2020 - 18
APR September/October 2020 - 19
APR September/October 2020 - 20
APR September/October 2020 - 21
APR September/October 2020 - 22
APR September/October 2020 - 23
APR September/October 2020 - 24
APR September/October 2020 - 25
APR September/October 2020 - 26
APR September/October 2020 - 27
APR September/October 2020 - 28
APR September/October 2020 - 29
APR September/October 2020 - 30
APR September/October 2020 - 31
APR September/October 2020 - 32
APR September/October 2020 - 33
APR September/October 2020 - 34
APR September/October 2020 - 35
APR September/October 2020 - 36
APR September/October 2020 - 37
APR September/October 2020 - 38
APR September/October 2020 - 39
APR September/October 2020 - 40
APR September/October 2020 - 41
APR September/October 2020 - 42
APR September/October 2020 - 43
APR September/October 2020 - 44
APR September/October 2020 - 45
APR September/October 2020 - 46
APR September/October 2020 - 47
APR September/October 2020 - 48
APR September/October 2020 - 49
APR September/October 2020 - 50
APR September/October 2020 - 51
APR September/October 2020 - 52
APR September/October 2020 - 53
APR September/October 2020 - 54
APR September/October 2020 - 55
APR September/October 2020 - 56
APR September/October 2020 - 57
APR September/October 2020 - 58
APR September/October 2020 - 59
APR September/October 2020 - 60
APR September/October 2020 - 61
APR September/October 2020 - 62
APR September/October 2020 - 63
APR September/October 2020 - 64
APR September/October 2020 - 65
APR September/October 2020 - 66
APR September/October 2020 - 67
APR September/October 2020 - 68
APR September/October 2020 - 69
APR September/October 2020 - 70
APR September/October 2020 - 71
APR September/October 2020 - 72
APR September/October 2020 - 73
APR September/October 2020 - 74
APR September/October 2020 - 75
APR September/October 2020 - 76
APR September/October 2020 - 77
APR September/October 2020 - 78
APR September/October 2020 - 79
APR September/October 2020 - 80
APR September/October 2020 - 81
APR September/October 2020 - 82
APR September/October 2020 - 83
APR September/October 2020 - 84
APR September/October 2020 - 85
APR September/October 2020 - 86
APR September/October 2020 - 87
APR September/October 2020 - 88
APR September/October 2020 - 89
APR September/October 2020 - 90
APR September/October 2020 - 91
APR September/October 2020 - 92
APR September/October 2020 - 93
APR September/October 2020 - 94
APR September/October 2020 - 95
APR September/October 2020 - 96
APR September/October 2020 - 97
APR September/October 2020 - 98
APR September/October 2020 - 99
APR September/October 2020 - 100
APR September/October 2020 - 101
APR September/October 2020 - 102
APR September/October 2020 - 103
APR September/October 2020 - 104
APR September/October 2020 - 105
APR September/October 2020 - 106
APR September/October 2020 - 107
APR September/October 2020 - 108
APR September/October 2020 - 109
APR September/October 2020 - 110
APR September/October 2020 - 111
APR September/October 2020 - 112
APR September/October 2020 - 113
APR September/October 2020 - 114
APR September/October 2020 - 115
APR September/October 2020 - 116
APR September/October 2020 - 117
APR September/October 2020 - 118
APR September/October 2020 - 119
APR September/October 2020 - 120
APR September/October 2020 - 121
APR September/October 2020 - 122
APR September/October 2020 - 123
APR September/October 2020 - 124
APR September/October 2020 - 125
APR September/October 2020 - 126
APR September/October 2020 - 127
APR September/October 2020 - 128
APR September/October 2020 - 129
APR September/October 2020 - 130
APR September/October 2020 - 131
APR September/October 2020 - 132
APR September/October 2020 - 133
APR September/October 2020 - 134
APR September/October 2020 - 135
APR September/October 2020 - 136
APR September/October 2020 - 137
APR September/October 2020 - 138
APR September/October 2020 - 139
APR September/October 2020 - 140
APR September/October 2020 - 141
APR September/October 2020 - 142
APR September/October 2020 - 143
APR September/October 2020 - 144
APR September/October 2020 - 145
APR September/October 2020 - 146
APR September/October 2020 - 147
APR September/October 2020 - 148
APR September/October 2020 - 149
APR September/October 2020 - 150
APR September/October 2020 - 151
APR September/October 2020 - 152
APR September/October 2020 - 153
APR September/October 2020 - 154
APR September/October 2020 - 155
APR September/October 2020 - 156
APR September/October 2020 - 157
APR September/October 2020 - 158
APR September/October 2020 - 159
APR September/October 2020 - 160
APR September/October 2020 - 161
APR September/October 2020 - 162
APR September/October 2020 - 163
APR September/October 2020 - 164
APR September/October 2020 - 165
APR September/October 2020 - 166
APR September/October 2020 - 167
APR September/October 2020 - 168
APR September/October 2020 - Cover3
APR September/October 2020 - Cover4
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/apr-innovations-at-interphex-guide-april-2022
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/APRNovDec2020
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/APRSeptOct2020
https://www.nxtbookmedia.com